Montelair Hexal (Montelukast)

Montelukast, the active ingredient in Montelair Hexal, is a leukotriene receptor antagonist presented as tablets for oral use. It is used to manage asthma, allergic rhinitis and exercise‑induced bronchoconstriction in both adults and children who require long‑term control of airway inflammation. This therapy also helps reduce symptoms and improve quality of life.

GNH USA supplies Montelair Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Montelukast is a leukotriene receptor antagonist used to treat conditions mediated by cysteinyl leukotrienes. - Asthma: Improves control of chronic asthma by reducing bronchoconstriction and inflammation. - Allergic rhinitis: Relieves nasal congestion, sneezing and itching associated with seasonal or perennial allergic rhinitis. - Exercise‑induced bronchoconstriction: Prevents airway narrowing that occurs during or after physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate headache reported. - Abdominal pain: occasional stomach discomfort or cramps. - Nausea: feeling of queasiness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Allergic reactions: rash, angioedema or anaphylaxis requiring immediate medical attention. - Neuropsychiatric events: agitation, depression, or suicidal thoughts, reported rarely.

When prescribing Montelukast, clinicians should consider several precautionary measures. - Indication verification: confirm diagnosis of asthma, allergic rhinitis or exercise‑induced bronchoconstriction before use. - Age considerations: safety in children under 12 months has not been established; follow pediatric guidelines. - Pregnancy and lactation: use only if potential benefit outweighs risk, as data are limited. - Drug interactions: review concomitant medications for potential major interactions. - Monitoring: observe for neuropsychiatric symptoms, especially in adolescents. - Store at ambient temperature: keep below 25 °C, protect from moisture in original packaging.

Montelukast may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Ritonavir: strong CYP3A4 inhibition can increase montelukast plasma levels, risking toxicity. - Phenobarbital: strong CYP3A4 induction may reduce montelukast exposure, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Fluconazole: moderate CYP3A4 inhibition may modestly raise montelukast levels. - Carbamazepine: enzyme induction may lower montelukast concentrations. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.